Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217021 · ClinicalTrials.gov registry record · Early Phase 1
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
A Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT01217021 is a Early Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 10 participants.
The verdict
NCT01217021, a Early Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research will look at how the brain may change in people with Alzheimer disease (AD). The purpose of this research is to find out whether changes in the brain in people with Alzheimer disease can be detected using a brain imaging test. Most people with Alzheimer disease have changes in the brain that result in deposits of a protein called beta-amyloid. In this study, the investigators will be using a radioactive drug, \[18F\]MNI-558 that binds to beta-amyloid. This drug is experimental and has not been approved by the FDA. Brain imaging using PET (positron emission tomography) will be done to see if the investigators can evaluate the areas of beta-amyloid in the subjects with Alzheimer disease. The investigators will compare these scans with those done in healthy normal volunteers. PET is a brain-scanning test used in medicine and scientific research to see how the brain is working. The PET imaging test used in this study is not being done for diagnostic purposes.
Interventions
- DRUG [18F] MNI-558
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217021
The ClinicalTrials.gov registry entry for NCT01217021 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] MNI-558 is the first listed.
NCT01217021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01217021 about?
NCT01217021 is a clinical study titled "Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558". This research will look at how the brain may change in people with Alzheimer disease (AD). The purpose of this research is to find out whether changes in the brain in people with Alzheimer disease can be detected using a brain imaging test. Most people with Alzheimer disease have changes in the bra...
What is the current status of trial NCT01217021?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2010-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01217021?
The interventions under investigation include: [18F] MNI-558 (DRUG).
Who is sponsoring clinical trial NCT01217021?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.